Left Atrial Appendage Devices for Stroke Prevention in Atrial Fibrillation
详细信息 查看全文
- 作者：Sarah K. Hussain (1)
Rohit Malhotra (1)
John P. DiMarco (1) - 关键词：Atrial fibrillation ; Stroke prevention ; Left atrial appendage occlusion devices
- 刊名：Journal of Cardiovascular Translational Research
- 出版年：2014
- 出版时间：June 2014
- 年：2014
- 卷：7
- 期：4
- 页码：458-464
- 全文大小：
- 参考文献：1. Hart, R. G., Halperin, J. L., Pearce, L. A., Anderson, D. C., Kronmal, R. A., McBride, R., et al. (2003). Lessons from the stroke prevention in atrial fibrillation trials. / Annals of Internal Medicine, 138, 831-38. CrossRef
2. Go, A. S., Hylek, E. M., Phillips, K. A., Chang, Y., Henault, L. E., Selby, J. V., et al. (2001). Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. / JAMA, 285, 2370-375. CrossRef
3. Knecht, S., Oelschl?ger, C., Duning, T., Lohmann, H., Albers, J., Stehling, C., et al. (2008). Atrial fibrillation in stroke-free patients is associated with memory impairment and hippocampal atrophy. / European Heart Journal, 29, 2125-132. CrossRef
4. Stroke prevention in atrial fibrillation investigators. (1991). Stroke Prevention in Atrial Fibrillation Study. / Circulation, 84, 527-39.
5. Birman-Deych, E., Radford, M. J., Nilasena, D. S., & Gage, B. F. (2006). Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation. / Stroke, 37, 1070-074. CrossRef
6. Hylek, E. M., Evans-Molina, C., Shea, C., Henault, L. E., & Regan, S. (2007). Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. / Circulation, 115, 2689-696. CrossRef
7. Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., et al. (2009). Dabigatran versus warfarin in patients with atrial fibrillation. / New England Journal of Medicine, 361, 1139-151. CrossRef
8. Granger, C. B., Alexander, J. H., McMurray, J. J., Lopes, R. D., Hylek, E. M., Hanna, M., et al. (2011). Apixaban versus warfarin in patients with atrial fibrillation. / New England Journal of Medicine, 365, 981-92. CrossRef
9. Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., et al. (2011). Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. / New England Journal of Medicine, 365(10), 883-91.
10. Wallentin, L., Yusuf, S., Ezekowitz, M. D., Yusuf, S., Ezekowitz, M. D., Alings, M., et al. (2010). Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. / Lancet, 376, 975-83. CrossRef
11. Sánchez-Quintana, D., Pizarro, G., López-Mínguez, J. R., Ho, S. Y., & Cabrera, J. A. (2013). Standardized review of atrial anatomy for cardiac electrophysiologists. / Journal of Cardiovascular Translational Research, 6(2), 124-44. CrossRef
12. Blackshear, J. L., & Odell, J. A. (1996). Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. / Annals of Thoracic Surgery, 61, 755-59. CrossRef
13. Park, J. W., Bethencourt, A., Sievert, H., Santoro, G., Meier, B., Walsh, K., et al. (2011). Left atrial appendage closure with AMPLATZER cardiac plug in atrial fibrillation: initial European experience. / Catheterization and Cardiovascular Interventions, 77, 700-06. CrossRef
14. Freixa, X., Chan, J. L., Tzikas, A., Garceau, P., Basmadjian, A., & Ibrahim, R. (2013). The Amplatzer?/sup> Cardiac Plug 2 for left atrial appendage occlusion: novel features and first-in-man experience. / EuroIntervention, 8(9), 1094-098. CrossRef
15. Meier, B., Palacios, I., Windecker, S., Rotter, M., Cao, Q. L., Keane, D., et al. (2003). Transcatheter left atrial appendage occlusion with AMPLATZER devices to obviate anticoagulation in patients with atrial fibrillation. / Catheterization and Cardiovascular Interventions, 60, 417-22. CrossRef
16. Park, J. W. (2012). Acute safety results from ACP European multicenter post market observational study. / EuroIntervention, 8(Suppl. N), 314.
17. Park, J. W. (2012). Results of the AMPLATZER Cardiac Plug European Multicenter Observational Study. Presented at the Transcatheter Cardiovascular Therapeutics Conference.
18. Lam, Y., Yip, G. W., Yu, C. M., Chan, W. W., Cheng, B. C., Yan, B. P., et al. (2012). Left atrial appendage closure with AMPLATZER Cardiac Plug for stroke prevention in atrial fibrillation: initial Asia–Pacific experience. / Catheterization and Cardiovascular Interventions, 79, 794-00. CrossRef
19. Kefer, J., Vermeersch, P., Budts, W., De Potter, T., Aminian, A., Benit, E., et al. (2013). Transcatheter percutaneous left atrial appendage closure for stroke prevention in atrial fibrillation: the Belgian registry. / Acta Cardiologica, 68(6), 551-58.
20. Holmes, D. R., Reddy, V. Y., Turi, Z. G., Doshi, S. K., Sievert, H., Buchbinder, M., et al. (2009). Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non–inferiority trial. / Lancet, 374, 534-42. CrossRef
21. Reddy, V. Y., M?bius-Winkler, S., Miller, M. A., Neuzil, P., Schuler, G., Wiebe, J., et al. Left atrial appendage closure with the watchman device in patients with a contraindication for oral anticoagulation: ASA-Plavix feasibility study with Watchman left atrial appendage closure technology (ASAP Study). / Journal of the American College of Cardiology, 61(25), 2551-556.
22. Reddy, V. Y., Doshi, S. K., Sievert, H., Buchbinder, M., Neuzil, P., Huber, K., et al. (2013). Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3 year follow-up of the PROTECT-AF (Watchman left atrial appendage system for embolic protection in patients with atrial fibrillation) trial. / Circulation, 127, 720-29. CrossRef
23. Reddy, V. Y., Doshi, S. K., Sievert, H., Buchbinder, M., Neuzil, P., Huber, K., et al.; PROTECT AF Investigators. Long term results of PROTECT–AF: the mortality effects of left atrial appendage closure versus warfarin for stroke prophylaxis in AF. / Circulation, 127(6), 720-29.
24. Landmesser, U., Holmes, D. R. Jr. Randomized trial of LAA closure vs warfarin for stroke/thromboembolic prevention in patients with non-valvular atrial fibrillation (PREVAIL). / European Heart Journal, 33(6), 698-04.
25. Reddy, V. Y., Holmes, D., Doshi, S. K., Neuzil, P., & Kar, S. (2011). Safety of percutaneous left atrial appendage closure: results from the Watchman left atrial appendage system for embolic protection in patients with AF (PROTECT–AF) clinical trial and the Continued Access registry. / Circulation, 123, 417-24. CrossRef
26. Sick, P. B., Schuler, G., Hauptmann, K. E., Grube, E., Yakubov, S., Turi, Z. G., et al. (2007). Initial worldwide experience with the WATCHMAN left atrial appendage system for stroke prevention in atrial fibrillation. / Journal of the American College of Cardiology, 49, 1490-495. CrossRef
27. Sick, P. B., Schuler, G., Hauptmann, K. E., Grube, E., Yakubov, S., Turi, Z. G., et al. Stroke prevention in non-valvular atrial fibrillation: long–term results after 6 years of the Watchman left atrial appendage occlusion pilot study. Presented at the ESC Congress 2012.
28. Bartus, K., Han, F. T., Bednarek, J., Myc, J., Kapelak, B., Sadowski, J., et al. (2013). Percutaneous left atrial appendage suture ligation using the LARIAT device in patients with atrial fibrillation: initial clinical experience. / Journal of the American College of Cardiology, 62, 108-18. CrossRef
29. Sievert, H., Lesh, M. D., Trepels, T., Omran, H., Bartorelli, A., Della Bella, P., et al. (2002). Percutaneous left atrial appendage transcatheter occlusion to prevent stroke in high-risk patients with atrial fibrillation: early clinical experience. / Circulation, 105(16), 1887-889. CrossRef
30. Toumanides, S., Sideris, E. B., Agricola, T., & Moulopoulos, S. (2011). Transcatheter patch occlusion of the left atrial appendage using surgical adhesives in high–risk patients with atrial fibrillation. / Journal of the American College of Cardiology, 58, 2236-240. CrossRef
31. Cheng, Y., McGregor, J., Sommer, R., Gray, W., Edmiston, D., Conditt, G., et al. Safety and biocompatibility of the Coherex WaveCrestTM left atrial appendage occluder in a 30–day canine study. Presented at the Transcatheter Cardiovascular Therapeutics Conference 2012.
32. The 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Valvular Heart Disease). / Journal of the American College of Cardiology, 52(13), e1-42, e1–e142.
33. Healey, J. S., Crystal, E., Lamy, A., Teoh, K., Semelhago, L., Hohnloser, S. H., et al. (2005). Left Atrial Appendage Occlusion Study (LAAOS): results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke. / American Heart Journal, 150, 288-93. CrossRef
34. Katz, E. S., Tsiamtsiouris, T., Applebaum, R. M., Schwartzbard, A., Tunick, P. A., & Kronzon, I. (2000). Surgical left atrial appendage ligation is frequently incomplete: a transesophageal echocardiograhic study. / Journal of the American College of Cardiology, 36, 468-71. CrossRef
35. Salzberg, S. P., Gillinov, A. M., Anyanwu, A., Castillo, J., Filsoufi, F., & Adams, D. H. (2008). Surgical left atrial appendage occlusion: evaluation of a novel device with magnetic resonance imaging. / European Journal of Cardio-Thoracic Surgery, 34(4), 766-70. CrossRef
36. Slater, A. D., Tatooles, A. J., Coffey, A., Pappas, P. S., Bresticker, M., Greason, K., Slaughter, M. S. (2012). Prospective clinical study of a novel left atrial appendage occlusion device. / The Annals of Thoracic Surgery, 93(6), 2035-038.
37. Camm, A. J., Lip, G. Y., De Caterina, R., Savelieva, I., Atar, D., Hohnloser, S. H., et al. (2012). The 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. / European Heart Journal, 33, 2719-747. - 作者单位：Sarah K. Hussain (1)
Rohit Malhotra (1)
John P. DiMarco (1)
1. The University of Virginia, Charlottesville, VA, USA - ISSN：1937-5395
文摘
Atrial fibrillation (AF) is the most commonly encountered clinical arrhythmia, and stroke prevention remains an integral part of management of AF. Long-term therapy with oral anticoagulants, though effective, has many limitations, and these limitations have encouraged the search for device-based alternatives. In patients with non-valvular AF, approximately 90?% of thrombi are thought to arise from the left atrial appendage (LAA). The LAA can be obliterated surgically or percutaneously, and this should reduce the incidence of systemic thromboembolic events in AF, ideally without the need for further anticoagulation. We explore the currently available LAA occlusion devices and the evidence behind these devices. Although additional evidence from randomized trials is required to fully characterize the safety and efficacy of all of these devices, LAA occlusion has the potential to offer an attractive alternative for those at high stroke risk but are under-protected because of contraindications to anticoagulant therapy.